Mold Illness & CIRS: The Complete Functional Medicine Guide

The patient has seen eight physicians. Maybe twelve. They've been told it's fibromyalgia. Or chronic fatigue. Or depression. Or anxiety. Their labs came back "normal." Their imaging was unremarkable. They're on an antidepressant that isn't working and a sleep aid that barely helps.

Then they get to you.

In my practice, this is one of the most common presentations I see in complex, chronically ill patients. And after years of working through these cases, I can tell you: a significant subset have Chronic Inflammatory Response Syndrome — CIRS — driven by mold biotoxin exposure. They're not imagining it. They're not anxious. They're sick.

The challenge is knowing what to look for. This guide walks through the full clinical picture: what CIRS is, why conventional medicine misses it, how to diagnose it, and how to approach treatment. If you're new to mold illness, this is your starting framework. If you've been working with these patients for years, maybe it fills in a few gaps.

---

What Is CIRS?

Chronic Inflammatory Response Syndrome is a multisystem, multi-symptom illness caused by biotoxin exposure in genetically susceptible individuals. The primary source is water-damaged buildings (WDB) harboring molds like Aspergillus, Stachybotrys, Penicillium, and Chaetomium — along with their mycotoxins: trichothecenes, ochratoxin A, aflatoxin, and gliotoxin.

The foundational model comes from Ritchie Shoemaker, MD, who spent decades characterizing the biotoxin pathway and developing a sequential treatment protocol that is now the most clinically validated approach to CIRS. [PMC11623837]

Here's the core mechanism. Biotoxins from WDB enter the body through inhalation, ingestion, or skin contact. In most people, the innate immune system processes and clears them. But roughly 25% of the population carries HLA-DRB1 haplotypes that impair their ability to clear biotoxins efficiently. [PMID 35989056] For these patients, biotoxins persist. The innate immune system stays activated. The result is a chronic, self-perpetuating inflammatory cascade that conventional labs don't measure and conventional medicine doesn't recognize.

This is not an adaptive immune response. There are no CIRS-specific antibodies. Standard allergy testing won't catch it. Immunoglobulin panels will be normal. The dysfunction is in the innate immune pathway — pattern recognition, complement activation, cytokine production.

---

The Genetic Piece: HLA-DRB1

Not everyone who lives in a moldy building gets CIRS. That's the part that confuses patients and frustrates their families.

The susceptibility is genetic. Specific HLA-DRB1 haplotypes — including 11-3-52B, 12-3-52B, 14-5-52B, and 7-2-53 — correlate with impaired biotoxin clearance. [Shoemaker Protocol; survivingmold.com] Carriers of these haplotypes cannot mount an effective antigen-presenting response to biotoxins. Without that, the biotoxins don't get flagged for clearance. They circulate. They bind to receptors. They trigger ongoing innate immune activation.

For your practice: when you identify one HLA-susceptible patient in a household, check the others. This explains why one person in a water-damaged home gets devastatingly ill while their spouse feels fine.

---

The CIRS Symptom Cluster

One thing that makes CIRS clinically distinctive — and clinically confusing — is the breadth of symptoms. Shoemaker's 37-symptom cluster spans virtually every organ system. [Shoemaker Protocol; survivingmold.com]

The major categories:

Neurological/Cognitive: Word-finding difficulty, short-term memory loss, difficulty concentrating, confusion, disorientation, difficulty with calculations. These are often the presenting complaints.

Pain: Muscle cramps, unusual pain, ice pick pain, joint pain, morning stiffness, headaches. The pain pattern is often described as atypical — not quite arthritis, not quite neuropathy.

Autonomic/Endocrine: Excessive thirst, increased urination, temperature dysregulation, sweats, static shock sensations.

Sensory: Light sensitivity, red eyes, blurred vision, tearing, skin sensitivity.

Respiratory/GI: Sinus problems, cough, shortness of breath, abdominal pain, diarrhea.

Mood: Mood swings, appetite swings, anxiety, depression.

No single symptom is pathognomonic. It's the cluster that matters. When I see a patient with multi-system symptoms across neurological, autonomic, pain, and sensory domains — with normal standard labs — CIRS is on my differential.

---

Why Conventional Medicine Misses CIRS

This is important to understand, because your patients will come in frustrated. They've been dismissed. They deserve an explanation.

CIRS doesn't appear in most medical training programs. It's not in UpToDate. There's no ICD-10 code that fully captures it. The standard workup — CBC, CMP, TSH, maybe ANA — misses every CIRS-specific biomarker. To find CIRS, you have to order tests that most conventional physicians don't know exist: C4a, TGF-beta-1, MSH, VIP, MMP-9. [PMC11623837]

The symptom overlap makes it worse. Fatigue plus cognitive impairment plus mood changes equals psychiatric referral in most conventional workups. Fibromyalgia and CFS diagnoses are landing spots when nothing else fits. Meanwhile, the actual driver — ongoing biotoxin-mediated innate immune activation — goes unaddressed. [PMID 35989056]

Here's a number worth knowing: somewhere between 10% and 25% of patients with chronic complex illness have a biotoxin component to their illness. [PMID 35989056] That's not rare. That's a lot of patients sitting in your waiting room with a diagnosis that doesn't explain their suffering.

---

Diagnosis: The CIRS Workup

Diagnosis requires combining clinical assessment with objective biomarkers. Here's the framework. (A detailed lab interpretation guide is covered separately.)

Visual Contrast Sensitivity (VCS) Test

Start here. The VCS test is free at survivingmold.com and takes about 10 minutes. It tests neurological function specifically affected by biotoxin exposure. Sensitivity is approximately 92% for mold illness. [Shoemaker Protocol; survivingmold.com] A positive VCS doesn't diagnose CIRS, but a negative VCS in a compliant patient makes CIRS significantly less likely.

HLA-DRB1 Genetic Typing

One-time test. Order through Quest or LabCorp. Identifies whether the patient carries susceptibility haplotypes. This doesn't diagnose CIRS — plenty of HLA-susceptible patients never develop it — but it explains why they can't clear biotoxins and informs treatment expectations.

Core Inflammatory Biomarkers

The essential panel:

• C4a — Complement activation marker. The most sensitive CIRS indicator. Values above 2,830 ng/mL are significantly elevated. Requires careful cold-chain shipping — complement is labile and false lows are common with improper handling. [Shoemaker Protocol; survivingmold.com]
• TGF-beta-1 — Regulatory cytokine. Elevated above 2,380 pg/mL. Drives both fibrosis and paradoxical inflammatory activation. [Shoemaker Protocol; survivingmold.com]
• MMP-9 (Matrix Metallopeptidase-9) — Enzymatic marker of inflammation and blood-brain barrier permeability. Above 332 ng/mL. Elevated MMP-9 is the key driver of neurological symptoms. [PMID 35353713]
• MSH (Melanocyte Stimulating Hormone) — Regulatory neuropeptide. Low MSH (below 35 pg/mL) governs immune regulation, sleep, pain, gut motility, and endorphin production. Low MSH means the patient will not improve without active restoration. [Shoemaker Protocol; survivingmold.com]

Hormonal/Neuropeptide Markers

• VIP (Vasoactive Intestinal Polypeptide) — Below 23 pg/mL is low. Governs pulmonary function, gut motility, and neuroimmunomodulation. VIP is the last biomarker to recover and is the target of the final treatment step.
• VEGF — Below 31 pg/mL suggests impaired capillary perfusion.
• ADH/Osmolality — Dysregulation explains the excessive thirst, frequent urination, and static shock symptoms patients describe.

Environmental Assessment

ERMI (Environmental Relative Moldiness Index) or HERTSMI-2 testing for the home or workplace. Patients can order these directly. This matters for treatment: no protocol works if the patient remains in the exposure environment.

Urinary Mycotoxin Testing

Labs like Great Plains (now Mosaic) and Mosaic Diagnostics offer urinary mycotoxin panels measuring ochratoxin A, trichothecenes, aflatoxin, and gliotoxin. These can be useful for documenting exposure and for patient education, but they are not required for the Shoemaker protocol and don't replace biotoxin pathway biomarkers.

---

The Biotoxin Pathway: A Simplified Model

Understanding the pathway helps explain why the treatment has to be sequential.

Biotoxin exposure triggers innate immune activation. Complement proteins — particularly C4a — spike. TGF-beta-1 surges. MMP-9 elevates. This cytokine environment suppresses MSH production. Low MSH cascades into sleep disruption, pain amplification, gut motility problems, and impaired immune regulation.

Two downstream complications amplify the cycle.

MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci): A nasal colonizer found in a significant proportion of CIRS patients. MARCoNS produces exotoxins that further suppress MSH. [Shoemaker Protocol; survivingmold.com] As long as MARCoNS is present, MSH cannot recover — no matter what else you do. This is why nasal culture is part of the workup.

VIP depletion: VIP is downstream of MSH and TGF-beta-1. Chronic CIRS depletes VIP over time, causing pulmonary hypertension risk, altered gene expression, and impaired neuroimmunomodulation. VIP is the last biomarker to recover — and VIP supplementation fails if upstream steps haven't been addressed.

The pathway has dependencies. This is why treatment sequence matters.

---

Treatment Overview: The Shoemaker Protocol

A detailed step-by-step implementation guide is covered separately. Here's the framework.

Step 1: Remove the patient from exposure.

This is not optional. It is not Step 1 of 16 equal steps. It is the prerequisite for everything else. I've seen patients spend thousands on supplements and follow every protocol step perfectly while still living or working in a water-damaged building. They don't improve. Remove the exposure first. Confirm with ERMI testing. Consider mold remediation or relocation.

Step 2: Biotoxin binders.

Cholestyramine (CSM) or Welchol. These sequester biotoxins in the gut and prevent enterohepatic recirculation. CSM is more potent; Welchol is better tolerated. Gluten-free formulations matter for mold-susceptible patients who commonly have anti-gliadin antibody elevation. [PMC11623837]

Step 3: MARCoNS eradication.

Only initiated after CSM has reduced systemic biotoxin load. BEG spray (Bacitracin-EDTA-Gentamicin) intranasal, 30-day course. Confirm eradication with repeat culture before proceeding.

Step 4 and beyond: Sequential inflammatory and hormonal correction.

After clearance, the protocol addresses elevated MMP-9, low VEGF, HPA axis dysregulation, low amylose diet implementation, ADH/osmolality correction, leptin resistance, and ultimately — in the final steps — VIP restoration via compounded nasal spray.

FM modifications beyond Shoemaker:

In my practice, I layer in phospholipid support (phosphatidylcholine) for patients with significant neurological involvement, intravenous glutathione for mycotoxin-specific oxidative burden, activated charcoal and bentonite clay as adjunct binders in severe cases, and mitochondrial support. Mycotoxins are mitochondrial toxins with complex I inhibition — CoQ10, riboflavin, and alpha-lipoic acid have a role. [PMC8619365]

Low-amylose diet is protocol-standard but often needs specific guidance. Rice, corn, and potatoes are high-amylose. The dietary pattern looks like modified paleo: non-starchy vegetables, quality proteins, healthy fats.

---

HANS for CIRS Patients

CIRS is one of the most documentation-intensive conditions in functional medicine. A single follow-up visit involves tracking 8-12 biomarkers, protocol step progression, symptom cluster scoring, environmental status, and patient response over a 6-18 month treatment arc. Conventional EMRs aren't built for this.

HANS handles the complexity: structured notes for each protocol step, lab trend tracking across visits, and note generation that reflects the clinical reasoning behind each decision. When you're managing a panel of CIRS patients, the documentation burden is real. HANS is built to carry it.

---

Why CIRS Mastery Matters for Your Practice

The patients who get to you with this have been failed. Repeatedly. They've been dismissed, misdiagnosed, medicated for the wrong thing. When you correctly identify CIRS, work through the protocol, and watch their biomarkers normalize and their cognitive function return — that's the kind of outcome that doesn't happen in conventional medicine.

CIRS competency also differentiates you. Most integrative physicians haven't mastered the Shoemaker protocol. Most don't know their C4a from their TGF-beta-1. If you do — if you can take on the documentation complexity and run the full protocol — you become the practitioner that the most complex chronic illness patients find when they've exhausted every other option.

That's the position worth building.

---

Further Reading in This Series

• CIRS Lab Testing Guide: Interpreting Shoemaker Biomarkers — detailed reference ranges, panel interpretation, common testing errors
• Shoemaker Protocol: Step-by-Step FM Implementation — full 16-step walkthrough with FM modifications
• Mold Illness Brain Fog: What's Happening and How to Treat It — the neurobiology of CIRS-driven cognitive impairment and treatment approach

---

Peter Kozlowski, MD is a functional medicine physician and clinical educator. This content is intended for licensed medical practitioners.